Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Meibomian Glands Clear all
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 2, 2026, 2:41 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

NCT01797107
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Azasite
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

NCT04139798
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
NOV03, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lipids of the Human Tear Film and Their Effect on Tear Stability

NCT00803452
View directory record Official record
Conditions
Blepharitis
Interventions
doxycycline, azithromycin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional

TearCare MGX™ System With and Without Warming Hold

NCT07365735
View directory record Official record
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
localized heat therapy
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

NCT04469998
View directory record Official record
Conditions
Posterior Blepharitis, Meibomian Gland Dysfunction
Interventions
AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 2, 2026, 2:41 AM EDT
Not listed Not applicable Interventional

The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Meibomian Gland Function

NCT04309799
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Tear Restore Mask
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Innovations iLux Safety Study

NCT03055897
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
iLux 2020 System
Device
Lead sponsor
Tear Film Innovations, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

NCT04795752
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lipiflow vs iLux Patient Acceptance and Comfort Study

NCT04454983
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Lipiflow Thermal Pulsation System, iLux System
Device
Lead sponsor
Epstein, Arthur B., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

NCT03226769
View directory record Official record
Conditions
Meibomian Glands, Dry Eye Syndromes
Interventions
TrueTear™, Thermalon Dry Eye Compress
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 2, 2026, 2:41 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

NCT03788486
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

NCT02621593
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
M22-IPL
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Beverly Hills, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery

NCT01808560
View directory record Official record
Conditions
Blepharitis, Dry Eye Syndrome
Interventions
LipiFlow Pre-Treatment, LipiFlow Post-treatment
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Hoffman Estates, Illinois • Lake Villa, Illinois • Winchester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional

Feasibility of IPL Combined With RF for Treatment of DED Due to MGD

NCT05487547
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
IPL_RF_MGX
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York • Harrisburg, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

NCT03888378
View directory record Official record
Conditions
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Interventions
0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Azusa, California • Huntington Beach, California • Inglewood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 2, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

NCT01979887
View directory record Official record
Conditions
Meibomian Glands
Interventions
Meibum Expression
Procedure
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

NCT01521507
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
LipiFlow System, Warm Compress Therapy + Lid Scrub
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fayetteville, Arkansas • Laguna Hills, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease

NCT03658811
View directory record Official record
Conditions
Dry Eye
Interventions
intense pulsed light
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease

NCT06242860
View directory record Official record
Conditions
Evaporative Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
ELM
Device
Lead sponsor
Eyedetec Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Citrus Heights, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

iLux Treatment for Meibomian Gland Dysfunction (MGD)

NCT03055650
View directory record Official record
Conditions
Evaporative Dry Eye
Interventions
iLux 2020 System
Device
Lead sponsor
Tear Film Innovations, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Encinitas, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Phase 4 Interventional

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

NCT04413279
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
LipiFlow Thermal Pulsation, Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Procedure · Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 2, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

NCT04884243
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
CBT-006
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 2, 2026, 2:41 AM EDT